MedTrace Logo

High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay

NCT02699008 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 477

Last updated 2016-03-04

No results posted yet for this study

Summary

High on-treatment platelet reactivity to adenosine diphosphate was a important reason to cause ischemic events in antiplatelet therapy. Using single testing to definite HPR may miss the "true HPR" or over estimate HPR, which may lead to randomized trials failed. It is not known whether combined multiple platelet function testing could assist to ensure"ture"HPR and improve clinical outcomes.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Clopidogrel

Antiplatelet agent

DRUG

Ticagrelor

New P2Y12 receptor inhibitor antiplatelet agent

Sponsors & Collaborators

  • Wuhan Asia Heart Hospital

    lead OTHER

Principal Investigators

  • Zhou xin, MD · Wuhan Asia Heart Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-08-31
Completion
2015-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02699008 on ClinicalTrials.gov